Our 31 year old female patient with newly diagnosed CML in chronic phase is commenced on dasatinib 100 mg OD with the aim of gaining a faster deep molecular response (DMR).
3 years later (patient is now 34)…..
- She has tolerated the drug well – no evidence of pleural effusions
- She has had a complete haematological response (CHR)
- Her BCR-ABL1 to ABL1 ratio has been hovering around 0.05% for the last 2 years. She is now asking to stop the drug to start trying for a family
What is the evidence around stopping TKI therapy? How would you counsel the patient in the best way forward?
Please reply to us (@TeamHaem) on Twitter and always include #TeamHaem to allow others to follow your comments. Please join in the debate and learn about haematological problems along the way. The case will continue to evolve over the coming week so keep checking #TeamHaem on Twitter for more information.
Please note – all cases on TeamHaem are entirely fictional to protect patient confidentiality.
TeamHaem are not a position of authority. It is an educational platform to allow discussion and learning.